Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset
Abbott Laboratories (NYSE:ABT) agreed to acquire Exact Sciences for US$21b. The deal is set to reshape Abbott’s diagnostics business by adding a broad cancer testing platform. Management is also rolling out changes